A 150-Day, Prospective, Phase 4, Open-Label Study, Evaluating Patient Satisfaction and Symptom Improvement When Treating Male Hypogonadism With Testosterone Nasal Gel (Natesto™)
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 13 Oct 2017
At a glance
- Drugs Testosterone (Primary)
- Indications Hypogonadism
- Focus Therapeutic Use
- Acronyms MyT
- Sponsors Acerus Pharmaceuticals
- 10 Oct 2017 Planned End Date changed from 1 Apr 2017 to 1 Nov 2017.
- 10 Oct 2017 Planned primary completion date changed from 1 Apr 2017 to 1 Nov 2017.
- 10 Oct 2017 Status changed from recruiting to active, no longer recruiting.